Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Skin autofluorescence is associated with rapid renal function decline in subjects at increased risk of coronary artery disease.

Wang CC, Shen MY, Chang KC, Wang GJ, Liu SH, Chang CT.

PLoS One. 2019 May 22;14(5):e0217203. doi: 10.1371/journal.pone.0217203. eCollection 2019.

PMID:
31116778
2.

Characteristics of patients with endometrial hyperplasia under different air quality index conditions.

Chang FW, Hsu RJ, Liu SH.

Taiwan J Obstet Gynecol. 2019 Mar;58(2):282-287. doi: 10.1016/j.tjog.2019.01.021.

3.

Performance of trickling bed microbial fuel cell treating isopropyl alcohol vapor: Effects of shock-load and shut-down episodes.

Liu SH, Lin HH, Wen S, Lin CW.

Chemosphere. 2019 Jun;224:168-175. doi: 10.1016/j.chemosphere.2019.02.149. Epub 2019 Feb 23.

PMID:
30818194
4.

Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.

Costa MJ, Kudaravalli J, Ma JT, Ho WH, Delaria K, Holz C, Stauffer A, Chunyk AG, Zong Q, Blasi E, Buetow B, Tran TT, Lindquist K, Dorywalska M, Rajpal A, Shelton DL, Strop P, Liu SH.

Sci Rep. 2019 Feb 21;9(1):2443. doi: 10.1038/s41598-019-38745-x.

5.

[Distribution and Removal of Polycyclic Aromatic Hydrocarbons and Their Derivatives in SBR/MBBR Process].

Liu SH, Tian WJ, Zhou JR, Zhao J, Wang Z.

Huan Jing Ke Xue. 2019 Feb 8;40(2):747-753. doi: 10.13227/j.hjkx.201807099. Chinese.

PMID:
30628339
6.

RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models.

Wong OK, Tran TT, Ho WH, Casas MG, Au M, Bateman M, Lindquist KC, Rajpal A, Shelton DL, Strop P, Liu SH.

Oncotarget. 2018 Sep 11;9(71):33446-33458. doi: 10.18632/oncotarget.26002. eCollection 2018 Sep 11.

7.

Bioremediation capability evaluation of benzene and sulfolane contaminated groundwater: Determination of bioremediation parameters.

Yang CF, Liu SH, Su YM, Chen YR, Lin CW, Lin KL.

Sci Total Environ. 2019 Jan 15;648:811-818. doi: 10.1016/j.scitotenv.2018.08.208. Epub 2018 Aug 17.

PMID:
30138881
8.

A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics.

Costa MJ, Kudaravalli J, Liu WH, Stock J, Kong S, Liu SH.

PLoS One. 2018 Mar 19;13(3):e0194688. doi: 10.1371/journal.pone.0194688. eCollection 2018.

9.

A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.

Liu SH, Gu Y, Pascual B, Yan Z, Hallin M, Zhang C, Fan C, Wang W, Lam J, Spilker ME, Yafawi R, Blasi E, Simmons B, Huser N, Ho WH, Lindquist K, Tran TT, Kudaravalli J, Ma JT, Jimenez G, Barman I, Brown C, Chin SM, Costa MJ, Shelton D, Smeal T, Fantin VR, Pernasetti F.

Blood Adv. 2017 Jun 21;1(15):1088-1100. doi: 10.1182/bloodadvances.2016003921. eCollection 2017 Jun 27.

10.

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).

Zhang Y, Saavedra E, Tang R, Gu Y, Lappin P, Trajkovic D, Liu SH, Smeal T, Fantin V, De Botton S, Legrand O, Delhommeau F, Pernasetti F, Louache F.

Sci Rep. 2017 Aug 4;7(1):7305. doi: 10.1038/s41598-017-07848-8.

11.

Correction: Molecular exploration of hidden diversity in the Indo-West Pacific sciaenid clade.

Lo PC, Liu SH, Nor SAM, Chen WJ.

PLoS One. 2017 Jul 12;12(7):e0181511. doi: 10.1371/journal.pone.0181511. eCollection 2017.

12.

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.

Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE.

J Hematol Oncol. 2017 May 19;10(1):112. doi: 10.1186/s13045-017-0435-x.

13.

Molecular exploration of hidden diversity in the Indo-West Pacific sciaenid clade.

Lo PC, Liu SH, Nor SAM, Chen WJ.

PLoS One. 2017 Apr 28;12(4):e0176623. doi: 10.1371/journal.pone.0176623. eCollection 2017. Erratum in: PLoS One. 2017 Jul 12;12 (7):e0181511.

14.

Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates.

DeVay RM, Delaria K, Zhu G, Holz C, Foletti D, Sutton J, Bolton G, Dushin R, Bee C, Pons J, Rajpal A, Liang H, Shelton D, Liu SH, Strop P.

Bioconjug Chem. 2017 Apr 19;28(4):1102-1114. doi: 10.1021/acs.bioconjchem.7b00013. Epub 2017 Feb 13.

PMID:
28151644
15.

Virtue Existential Career Model: A Dialectic and Integrative Approach Echoing Eastern Philosophy.

Liu SH, Hung JP, Peng HI, Chang CH, Lu YJ.

Front Psychol. 2016 Nov 14;7:1761. eCollection 2016.

16.

RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.

Strop P, Tran TT, Dorywalska M, Delaria K, Dushin R, Wong OK, Ho WH, Zhou D, Wu A, Kraynov E, Aschenbrenner L, Han B, O'Donnell CJ, Pons J, Rajpal A, Shelton DL, Liu SH.

Mol Cancer Ther. 2016 Nov;15(11):2698-2708. Epub 2016 Aug 31.

17.

Nuclear IKKα mediates microRNA-7/-103/107/21 inductions to downregulate maspin expression in response to HBx overexpression.

Chen WS, Liu LC, Yen CJ, Chen YJ, Chen JY, Ho CY, Liu SH, Chen CC, Huang WC.

Oncotarget. 2016 Aug 30;7(35):56309-56323. doi: 10.18632/oncotarget.10462.

18.

[Distribution Characteristics and Source Apportionment of n-Alkanes in Water from Yellow River in Henan Section].

Feng JL, Xi NN, Zhang F, Liu SH, Sun JH.

Huan Jing Ke Xue. 2016 Mar 15;37(3):893-9. Chinese.

PMID:
27337879
19.

Controlling Indoor Air Pollution from Moxibustion.

Lu CY, Kang SY, Liu SH, Mai CW, Tseng CH.

Int J Environ Res Public Health. 2016 Jun 20;13(6). pii: E612. doi: 10.3390/ijerph13060612.

20.

Docosahexaenoic acid inhibits 12-O-tetradecanoylphorbol-13- acetate-induced fascin-1-dependent breast cancer cell migration by suppressing the PKCδ- and Wnt-1/β-catenin-mediated pathways.

Lii CK, Chang JW, Chen JJ, Chen HW, Liu KL, Yeh SL, Wang TS, Liu SH, Tsai CH, Li CC.

Oncotarget. 2016 May 3;7(18):25162-79. doi: 10.18632/oncotarget.7301.

Supplemental Content

Loading ...
Support Center